Aldeyra Therapeutics (ALDX) News
NASDAQ: ALDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.9163-0.0314 (-3.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ALDX news summary
We found 6 recent headlines mentioning Aldeyra Therapeutics (ALDX): 3 in the past week and 6 in the past 30 days, most often from Nasdaq. For price context, ALDX is down 3.31% at $0.9163. The most recent story, "argenx Meets Primary Endpoint in Phase II Celiac Disease Study", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Aldeyra Therapeutics headlines
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.NasdaqARGX, ALNY, AMRN, ALDX
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowAgios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.NasdaqAGIO, NVO, ALDX, ACIU
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.NasdaqNVO, ALDX, ACIU, PGEN
- Vertex Posts Positive Phase II Data on Kidney Disease DrugVRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.NasdaqVRTX, ALDX, ACIU, PGEN
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaGILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.NasdaqGILD, ALDX, ACIU, PGEN
- GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyGSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.NasdaqGSK, ALDX, ACIU, PGEN